Helmholtz researchers have created the first detailed protein map of specific sensory neurons that trigger pain. Their study, published in “ Nature Communications ,” will help researchers better understand the molecular mechanisms of chronic inflammatory pain and identify new drug targets.
Joint press release by the Max Delbrück Center
and the Helmholtz Centre for Infection Research
One in five people worldwide suffers from chronic inflammatory pain. Meanwhile, about two thirds of those affected find little relief from existing pain medications; new therapeutic approaches are urgently needed. “We first must understand precisely how sensory nerve cells trigger pain at the molecular level — in other words, which proteins are involved,” says Professor Gary Lewin, Group Leader of the Molecular Physiology of Somatosensory Perception lab at the Max Delbrück Center in Berlin.
To unravel these molecular processes, Lewin – who has been studying pain for four decades and recently discovered a previously unknown ion channel involved in pain perception – is working closely with systems biologist Dr. Fabian Coscia, Group Leader of the Spatial Proteomics lab at the same center. Coscia co-developed a method called Deep Visual Proteomics that makes it possible to determine the proteome — the complete set of proteins — of specific cells and to create maps detailing the spatial locations of individual proteins.
The researchers combined this technology with electrophysiological methods from Lewin’s group. This enabled them to first identify specific subtypes of pain neurons based on their function and then analyze their protein profiles. The result is a high-resolution molecular map of these nerve cells, which has been published in “Nature Communications.” The team also demonstrated how the technology can identify potential new drugs targets to treat chronic pain.
Dr. Sampurna Chakrabarti is the study’s first author and a former postdoctoral researcher in the Lewin lab who now heads the Pathways in Infection and Nociception group at the Helmholtz Centre for Infection Research in Braunschweig. Nociception refers to how our nerves respond to stimuli that trigger pain. Nerves in skin and other peripheral tissues – such as muscles and joints – that detect damaging stimuli are called nociceptors; they relay signals to the brain to initiate pain.
All nociceptors are not alike. “Until now, only the transcriptome – that is, the RNA level information of the different subsets of nociceptors – was known,” says Chakrabarti. “However, the actual functional components of all cells are the proteins formed from these transcripts – and we have now examined them in greater detail for the first time in two subtypes of nociceptors.” Using an electrophysiological method known as the patch-clamp technique, the team first identified and characterized two nociceptor subtypes – peptidergic and non-peptidergic – in the spinal ganglia of mice. Each of these subtypes respond differently to similar stimuli and may initiate pain of different quality and duration.
The researchers used around 50 neurons of each subtype to generate a specific protein map for each of the two cell types. Deep Visual Proteomics combines mass spectrometry with microscopy, artificial intelligence and robotics. Coscia and his team have so far mainly used this methodology for proteome analyses of cancer cells. “We have now shown for the first time that it can also be applied to nerve cells,” he says.
The team measured more than 6,000 proteins in these 50 neurons. A comparison with existing RNA data revealed that the transcriptome and proteome of the cells differ significantly in some cases – an indication that key functional processes only become visible at the protein level. “We provide a unique molecular map of pain-initiating neurons,” says Coscia. “It enables the identification of signaling pathways in these cells that have so far remained hidden.”
In an additional step, Chakrabarti and her colleagues wanted to understand which proteins sensitize nerve cells, contributing to chronic pain. They isolated both types of nociceptors from mouse dorsal root ganglia and exposed them to a molecule called Nerve Growth Factor (NGF), which is known to trigger chronic pain both animals and humans, such as in arthritis. Using Deep Visual Proteomics, the researchers were able to precisely identify the proteins produced after the cells were exposed to NGF.
Lewin and his team had already discovered that NGF plays an important role in chronic inflammatory pain more than 30 years ago. “In dogs and cats, pain can now be alleviated very effectively using antibodies that inhibit NGF,” says Lewin. “In humans, rare side effects have unfortunately prevented their use,” he adds. “But now we may have found an alternative approach: targeting a downstream protein responsible for NGF’s sensitizing effect.”
“We identified several proteins that were present in higher levels in a subset of nociceptors following treatment with NGF. The higher levels of these proteins could be linked to long term pain associated with inflammation,” says Chakrabarti. One of the proteins, an enzyme called B3GNT2, stood out in particular. “When we knocked out the corresponding gene in the cells, the inflammation-induced hyperactivity of nociceptors was reduced. Fewer cells responded to mechanical stimulus,” she says. In other words, the neurons had become less sensitive and would elicit much less pain.
In the future, the researchers plan to validate their findings in mice and humans. “More than 90 percent of all approved drugs now target proteins,” says Coscia. “This highlights how important it is to develop a better understanding of these molecules in order to identify new targets for more effective pain therapies and treatments for other neurological diseases.”
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association aims to transform tomorrow’s medicine through our discoveries of today. At locations in Berlin-Buch, Berlin-Mitte, Heidelberg and Mannheim, our researchers harness interdisciplinary collaboration to decipher the complexities of disease at the systems level – from molecules and cells to organs and the entire organism. Through academic, clinical, and industry partnerships, as well as global networks, we strive to translate biological discoveries into applications that enable the early detection of deviations from health, personalize treatment, and ultimately prevent disease. First founded in 1992, the Max Delbrück Center today inspires and nurtures a diverse talent pool of 1,800 people from over 70 countries. We are 90 percent funded by the German federal government and 10 percent by the state of Berlin.
Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defense mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases. www.helmholtz-hzi.de/en
Nature Communications
Experimental study
Animal tissue samples
Deep visual proteomics uncovers nociceptor diversity and pain targets
13-Apr-2026